A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 

Intalith CR

Manufacturer:Intas Pharmaceuticals manufactures Intalith CR.
Uses:The uses of Intalith CR include:
Indications 1.Treatment of mania and hypomania. 2.Lithium may also be tried in the treatment of some patients with recurrent bipolar depression, for which treatment with other antidepressants has been unsuccessful. 3.Prophylactic treatment of recurrent affective disorders. Dosage and Administration A simple treatment schedule has been evolved which, except for some minor variations, should be followed whether using LITHICARB FC therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later. 1. In patients of average weight (70kg) an initial dose of 400- 1,200mg of LITHICARB FC may be given as a single daily dose in the morning or on retiring. Alternatively, the dose may be divided and given morning and evening. The tablets should not be crushed, chewed or swallowed with hot liquids. When changing from other lithium preparations serum lithium levels should first be checked, then 2. LITHICARB FC therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow release preparations), a change of product should be regarded as initiation of new treatment. 3. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level. 4. The objective is to adjust the LITHICARB FC dose so as to maintain the serum lithium level permanently within the diurnal range of 0.5 - 1.5 mmol/L. In practice, the blood sample should be taken between 12 and 24 hours after the previous dose of LITHICARB FC. 'Target' serum lithium concentrations at 12 and 24 hours are shown in Table 1. LITHICARB FC tablets are scored, therefore they can be divided accurately to provide dosage adjustments as small as 125mg. Serum lithium levels should be monitored weekly until stabilisation is achieved. Table 1. Target serum lithium concentrations "Target" serum lithium concentration (mmol/L) At 12 hours At 24 hours Once daily dosage 0.7 - 1.0 0.5 - 0.8 Twice daily dosage 0.5 - 0.8 4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels, the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage, on development of intercurrent disease, signs of manic or depressive relapse, following significant change in sodium or fluid intake, or if signs of lithium toxicity occur. 5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of LITHICARB FC therapy, LITHICARB FC should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy. 6. In patients who show a positive response to LITHICARB FC therapy, treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see Precautions). Treatment of Acute Mania, Hypomania and Recurrent Bipolar Depression: It is likely that a higher than normal LITHICARB FC intake may be necessary during an acute phase and divided doses would be required here. Therefore, as soon as control of mania or depression is achieved, the serum lithium level should be determined and it may be necessary, dependent on the results, to lower the dose of LITHICARB FC and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended. Prophylactic Treatment of Recurrent Affective Disorders It is recommended that the described treatment schedule is followed. Use in the Elderly: In elderly patients or those below 50kg in weight, it is recommended that the starting dose be 400mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years. Use in Children and Adolescents Not recommended.
StrengthQtyPriceOrder Qty
450mg100 Tablets$64.35
450mg200(2 x 100) Tablets$111.81
450mg400(4 x 100) Tablets$149.70
Intalith CR available now from Health Plus Pharmacy.



<a href=http://www.healthpluspharmacy.com/BannerAdClicks.asp?AdID=2&AffID=1&Page=Products2.asp?Brand=Intalith+CR+%28Eskalith%2C+Generic+Lithium+Carbonate%29&T=a>Intalith CR</a>